# US 8,273,346 B2 · Method for increasing fructose digestion with strains of Bacillus coagulans and fructase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,273,346 B2
- Document ID: US8273346B2
- Status: Granted
- Kind: B2
- Application number: 12/365,798
- Filed: 2009-02-04
- Published: 2009-07-16
- Granted: 2012-09-25
- Earliest claimed: 1998-08-07
- Assignees: Ganeden Biotech, Inc.
- Inventors: Sean Farmer; Andrew Lefkowitz
- Web page: https://patentgrep.com/patent/US8273346B2

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/175: Amino acids
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.

## Claims

### Claim 1

A method for increasing fructose digestion in a subject, comprising identifying a subject suffering from fructose intolerance, and orally administering to said subject a composition comprising an effective amount of viable Bacillus coagulans bacteria wherein said bacteria are selected from the group consisting of GBI-20 (ATCC PTA-6085), GBI-30 (ATCC PTA-6086), and GBI-40 (ATCC PTA-6087) and an effective amount of a supplemental fructase to increase fructose digestion in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said subject is human.

### Claim 3 (depends on 1)

The method of claim 1, wherein said effective amount of fructase is from 1000 IU to 12,000 IU.

### Claim 4 (depends on 1)

The method of claim 1, wherein said fructase is an enzyme that catalyses the hydrolysis of fructose.

### Claim 5 (depends on 1)

The method of claim 1, wherein said composition is in the form of a capsule, a tablet, a powder, a liquid, or a food product.

### Claim 6 (depends on 1)

The method of claim 1, wherein said composition is administered once per day.